[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2,
Lovastatin
CAS: 75330-75-5
Molecular Formula: C24H36O5
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Names and Identifiers
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Physico-chemical Properties
| Molecular Formula | C24H36O5 |
| Molar Mass | 404.54 |
| Density | 1.12±0.1 g/cm3(Predicted) |
| Melting Point | 175°C |
| Boling Point | 559.2±50.0 °C(Predicted) |
| Specific Rotation(α) | D25 +323° (c = 0.5 g in 100 ml acetonitrile) |
| Flash Point | 185.304°C |
| Water Solubility | 0.0004 mg/mL at 25 ºC |
| Solubility | Soluble in chloroform, soluble in acetone, slightly soluble in methanol, insoluble in water. |
| Vapor Presure | 0Pa at 25℃ |
| Appearance | White crystalline powder |
| Color | White |
| Merck | 14,5586 |
| pKa | 13.49±0.40(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. |
| Refractive Index | 320 ° (C=0.5, CH3CN) |
| MDL | MFCD00072164 |
| Physical and Chemical Properties | Melting Point 175°C water-soluble 0.0004 mg/mL at 25°C |
| Use | Cardiovascular system medication, can prevent the development of arteriosclerosis, reduce the risk of myocardial infarction and so on |
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| UN IDs | 3077 |
| WGK Germany | 3 |
| RTECS | EK7907000 |
| HS Code | 29322090 |
| Hazard Class | 9 |
| Packing Group | III |
| Toxicity | LD50 orally in mice: >1000 mg/kg (Endo) |
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Reference
| Reference Show more | 1. Wei Tang, Fei Chen. Mutation Breeding of Monacolin K-producing Monascus strains [J]. Jiangsu Agricultural Sciences 2013(02):306-308. 2. Yin Chaomin, fan Xiuzhi, Liu Chunyou, etc. Optimization of fermentation medium for production of lovastatin from Pleurotus ostreatus [J]. Journal of Nuclear-Agricultural Sciences, 2020, v.34(01):145-152. 3. Liu runpu, Sun Xiaodong, Li Yuheng, Wei Rui. Determination of monakycline K in Monascus rice fermented by Monascus A13 and Fen [J]. China condiment, 2020,45(08):132-134. 4. Zhang Xingxing, Mao Qingli, Sun Jun, Zhou Hanbo, Zhong Xiaodan, Wu Jiqin, Yan Ze, Tao Xin, Zhang Jie. Determination of lovastatin in Monascus fermented food by high performance liquid chromatography [J]. China Brewing, 2020,39(05):193-196. 5. Wu Enkai, Zhang Tingting, Peng Chunxiu, etc. Effect of Pu'er tea tea brown pigment on metabolic syndrome in rats under swing exercise based on metabonomics [J]. Food Science, 2019, 40(19). 6. Zhen, Z.; xiong, X.; liu, Y.; zhang, J.; wang, S.; li, L.; gao, M. NaCl Inhibits Citrinin and Stimulates Monascus Pigments and Monacolin K Production. Toxins 2019, 11, 118. https://doi.org/10.3390/toxins11020118 7. [IF=4.171] Ya-ping Huang et al."Protective effect and mechanism of Monascus-fermented red yeast rice against colitis caused by Salmonella enterica serotype Typhimurium ATCC 14028."Food Funct. 2020 Jul;11(7):6363-6375 8. [IF=3.638] Minmin Zou et al."Submerged fermentation of Ginkgo biloba seed powder using Eurotium cristatum for the development of ginkgo seeds fermented products."J Sci Food Agr. 2021 Mar;101(5):1782-1791 9. [IF=2.162] Chongyan Zhao et al."Process optimization in ginseng fermentation by Monascus ruber and study on bile acid-binding ability of fermentation products in vitro."Prep Biochem Biotech. 2021;51(2):120-126 10. [IF=5.396] Xiaojie Lu et al.The differential modulatory effects of Eurotium cristatum on the gut microbiota of obese dogs and mice are associated with improvements in metabolic disturbances.Food Funct. 2021 Dec;12(24):12812-12825 11. [IF=4.412] Wen Zhang et al."Efficiency Assessment of Bacterial Cellulose on Lowering Lipid Levels In Vitro and Improving Lipid Metabolism In Vivo."MOLECULES. 2022 Jan;27(11):3495 |
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Nature
Open Data Verified Data
White Crystal, melting point 174.5 °c (under nitrogen).
Last Update：2024-01-02 23:10:35
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Preparation Method
Open Data Verified Data
obtained by fermentation.
Last Update：2022-01-01 09:10:57
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Standard
Authoritative Data Verified Data
This product is (S)-2-methylbutanoic acid (4R,6R)-6-[2-[(1S, 2S, 6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2, 6-dimethyl-1-naphthyl] ethyl] tetrahydro-4-hydroxypyran-2-one -8-ester. The lovastatin content (C24H3605) shall not be less than 98.5% calculated on a dry basis.
Last Update：2024-01-02 23:10:35
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline or crystalline powder; Odorless, tasteless, slightly hygroscopic.
- This product is soluble in chloroform, soluble in acetone, slightly soluble in ethanol, ethyl acetate or acetonitrile, insoluble in water.
specific rotation
take this product, precision weighing, add acetonitrile to dissolve and dilute the moment to make a solution containing about 5mg per lml, according to the law (General 0621), the specific rotation was 325 ° to 340 °.
Last Update：2022-01-01 14:19:21
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Use
Open Data Verified Data
developed by Merk Sharp & Dohme, first launched in the United States in 1987. The product for cholesterol-lowering drugs, can significantly reduce the concentration of serum total cholesterol, after oral hydrolysis, inhibition of cholesterol synthesis. It is clinically used for heterozygous familial hypercholesterolemia, severe and mild primary hypercholesterolemia, and can also be used as an adjunct to diet therapy to reduce excessive cholesterol and low-density protein cholesterol levels.
Last Update：2022-01-01 09:10:57
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Differential diagnosis
Authoritative Data Verified Data
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take this product, dissolve and quantitatively dilute with acetonitrile to make a solution containing about 10ug per lml, and measure by UV-Vis spectrophotometry (General rule 0401), at 230nm, there is a maximum absorption at the wavelength of 238nm and 246nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 802).
Last Update：2022-01-01 14:19:22
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Safety
Open Data Verified Data
mouse oral LDsa: >1000mg/kg.
Last Update：2022-01-01 09:10:58
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Exam
Authoritative Data Verified Data
Related substances
take this product, add acetonitrile to dissolve and dilute to make a solution containing about 0.4mg per 1 ml as a test solution, A solution containing about 0.4ug per 1 ml was prepared as a control solution by quantitative dilution with acetonitrile. According to the high performance liquid chromatography (General 0512) test, I octa-alkyl silane bonded silica gel was used as the filler; Mobile phase A was 0.01% phosphoric acid solution, mobile phase B was acetonitrile, and the flow rate was 1.0ml per minute, the gradient elution was carried out according to the following table; The column temperature was 40°C; The detection wavelength was 238nm. Take 1 mg of simvastatin, put it in 50ml measuring flask, add acetonitrile to dissolve, add 5ml of test solution, dilute it with acetonitrile to scale, shake well, inject 10ul into liquid chromatograph, record chromatogram, the resolution of lovastatin peak and simvastatin peak should be more than 5.0. 10ul of the test solution and the control solution were respectively injected into the liquid chromatograph, and the chromatograms were recorded. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be more than 3 times (0.3%) of the area of the main peak of the control solution; the sum of each impurity peak area shall not be greater than l0 times (1.0%) of the main peak area of the control solution.
loss on drying
take this product and dry under reduced pressure at 60°C for 3 hours, and the weight loss shall not exceed 0.3% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.2%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 20 parts per million of heavy metal when examined by law (General rule 0821, Law II).
Last Update：2022-01-01 14:19:23
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane was used as the filler; Acetonitrile-0.01% phosphoric acid (60:40) was used as the mobile phase; The detection wavelength was 238nm. The number of theoretical plates is not less than 3000 calculated from the lovastatin peak.
assay
take about 20mg of this product, precision weighing, put it in a 100ml measuring flask, add acetonitrile to dissolve and dilute to the scale, shake, as a test solution, take 10 u1, human liquid chromatograph was used and the chromatogram was recorded. Another lovastatin control, precision weighing, the same method for determination. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 14:19:23
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Category
Authoritative Data Verified Data
hypolipidemic drugs.
Last Update：2022-01-01 14:19:24
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Storage
Authoritative Data Verified Data
light shielding and sealed storage.
Last Update：2022-01-01 14:19:24
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Lovastatin tablets
Authoritative Data Verified Data
This product contains lovastatin (C24H3S05) should be labeled amount of 90.0% ~ 110.0%.
trait
This product is white or off-white.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of fine powder of this product, add ethanol to dissolve lovastatin and dilute it to make a solution containing lovastatin 10ug per 1 ml, filter it, and take the filtrate, absorption maxima were determined by UV-Vis spectrophotometry (General 0401) at wavelengths of 230nm, 238nm and 246nm.
examination
- Related substances take an appropriate amount of fine powder of this product, add acetonitrile to dissolve lovastatin and dilute it to make a solution containing 0.4mg lovastatin per 1 ml, filter it, and take the continued filtrate as the test solution; take 1 ml of precision, 100ml flask, diluted with acetonitrile to scale, shake, as a control solution. The determination was carried out according to the method for lovastatin related substances. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (1.0%); the sum of each impurity peak area shall not be greater than 2 times (2.0%) of the main peak area of the control solution.
- Content uniformity take 1 tablet of this product, put it in 50ml measuring flask (10 mg specification) or in 100ml measuring flask (20mg specification), add appropriate amount of acetonitrile, sonicate for about 10 minutes to dissolve lovastatin, cool, dilute to scale with acetonitrile, shake, filter, and take the filtrate as a test solution. The content of each tablet shall be measured and calculated according to the law according to the method under the content determination item, and shall comply with the regulations (General rule 0941).
- dissolution of this product, according to the dissolution and release determination method (General 0931 second method), with 2% sodium dodecyl sulfate phosphate solution (sodium dihydrogen phosphate 1.38g, add water 900ml to dissolve, adjust the pH value to 7.0 with sodium hydroxide test solution, add water to 1000ml)900ml as dissolution medium, rotate speed is 50 rpm, operate according to law, after 30 minutes, take appropriate amount of solution, filter, take the filtrate as a test solution. In addition, take the lovastatin reference substance, precisely weigh it, add an appropriate amount of acetonitrile to dissolve it, and quantitatively dilute it with the dissolution medium to make a solution containing about lOug (0mg specification) or 20ug(20mg specification) per 1 ml, as a control solution. According to the method under the content determination item, the dissolution amount of each tablet was calculated by the peak area according to the external standard method. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
Take 20 tablets of this product, precision weighing, fine grinding, precision weighing an appropriate amount (about 20mg equivalent to lovastatin), put it in a 100ml measuring flask, add about 80ml of acetonitrile, the lovastatin was dissolved by shaking, diluted to the scale with acetonitrile, shaken, filtered, and the filtrate was taken as a test solution, and measured according to the method under the lovastatin content measurement item.
category
Same as lovastatin.
specification
(l ) 10mg ( 2 ) 20mg
storage
protected from light and sealed.
Last Update：2022-01-01 14:19:25
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Lovastatin Capsules
Authoritative Data Verified Data
This product contains lovastatin (C24H3S05) should be labeled the amount of 90.0% ~ 110.0%.
trait
The content of this product is white or white powder.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of the contents of this product, add ethanol to dissolve lovastatin and dilute it to make a solution containing about 10% lovastatin per 1 ml, filter it, take the filtrate, and measure it by spectrophotometry (General rule 0401), there is maximum absorption at wavelengths of 230nm, 238nm and 246nm.
examination
- Related substances the contents of this product are mixed evenly, and an appropriate amount is taken. Add acetonitrile to dissolve lovastatin and dilute it to make a solution containing 0.4mg lovastatin per 1 ml, and filter it, the filtrate was taken as a test solution; 1 ml was accurately measured, placed in a 100ml measuring flask, diluted to a scale with acetonitrile, and shaken to obtain a control solution. The determination was carried out according to the method for lovastatin related substances. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (1.0%); the sum of each impurity peak area shall not be greater than 3 times (3.0%) of the main peak area of the control solution.
- Content uniformity: Take 1 capsule of this product, pour out the content, put it in a 50ml (specification lOmg) or 100ml (specification 20mg) measuring flask, add an appropriate amount of acetonitrile, and sonicate for about 10 minutes to dissolve lovastatin, cool, dilute to scale with acetonitrile, shake, filter, and take the filtrate as a test solution. According to the method under the content determination item, the content of each grain shall be determined and calculated according to law, and the provisions shall be met (General rule 0941).
- dissolution of this product, according to the dissolution and release determination method (General 0931 first method), with 2% sodium dodecyl sulfate phosphate solution (sodium dihydrogen phosphate 1.38g, add water 900ml to dissolve, adjust the pH value to 7.0 with sodium hydroxide test solution, add water to 100 ml) as the dissolution medium, the rotation speed is rpm, and operate according to law. After 45 minutes, the appropriate amount of the solution was taken, filtered, and the filtrate was taken as the test solution. In addition, take the lovastatin reference substance, precisely weigh it, add an appropriate amount of acetonitrile to dissolve it, and quantitatively dilute it with dissolution medium to make a solution containing about 10ug(10mg specification) or 20ug(20mg specification) per 1 ml, as a reference solution, the dissolution amount of each tablet was calculated by the peak area according to the external standard method as measured by the method under the content measurement item. The limit is 70% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0102).
Content determination
take this product 20 tablets, precision weighing, calculate the average loading. Mix the contents evenly, weigh an appropriate amount (about 20mg of lovastatin) accurately, put it in a 100ml measuring flask, add about 80ml of acetonitrile, shake to dissolve lovastatin, dilute it with acetonitrile to scale, shake well, filter, and take the continued filtrate as the test solution. Lovastatin content was determined according to the method under the item of determination, obtained.
category
Same as lovastatin.
specification
(1) lOmg (2)20mg
storage
sealed, stored in a cool place.
Last Update：2022-01-01 14:19:26
[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2, - Lovastatin granules
Authoritative Data Verified Data
This product containing lovastatin (C24H3605) should be labeled the amount of 90.0% ~ 110.0%.
trait
This product is white or white particles.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of fine powder of this product, add ethanol to dissolve lovastatin and dilute it to make a solution containing lovastatin 10ug per 1 ml, filter it, and take the filtrate, as determined by UV-visible spectrophotometry (General 0401), there is an absorption maximum at wavelengths of 230nm, 238nm and 246nm.
examination
- weight loss on drying this product shall be dried under reduced pressure at 60°C for 3 hours with phosphorus pentoxide as desiccant, and the weight loss shall not exceed 2.0% (General rule 0831).
- others should comply with the relevant provisions under The granule (General Principle 0104).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler, acetonitrile-phosphate buffer (pH 4.0)(take potassium dihydrogen phosphate 3.45g, dissolve in water 900ml, the pH value was adjusted to 4.0 with dilute phosphoric acid, diluted to ML with water)-methanol (5:3:1) as mobile phase; The detection wavelength was 238nm. The number of theoretical plates is not less than 3000 calculated from the lovastatin peak.
- the contents under the item of difference in loading amount were measured, mixed evenly, ground finely, accurately weighed to take an appropriate amount (about 20mg equivalent to lovastatin), placed in a 100ml measuring flask, and added about 80ml of mobile phase, shake to dissolve lovastatin, dilute to scale with mobile phase, shake well, filter, take filtrate as test solution, take l0ul accurately, inject into liquid chromatograph, record chromatogram; in addition, an appropriate amount of lovastatin reference substance was accurately weighed, dissolved and quantitatively diluted with mobile phase to make a solution containing about 0.2mg per 1 ml, and determined by the same method. According to the external standard method to calculate the peak area, that is.
category
Same as lovastatin.
specification
20mg
storage
protected from light and sealed.
Last Update：2022-01-01 14:19:26
![[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2,](http://res.chembk.com/assets/str/2d/7/75/75330-75-5.png)
Supplier List
Multiple SpecificationsSpot supply
Product Name: Simvastatin Impurity 5（Simvastatin EP Impurity E） Visit Supplier Webpage Request for quotationCAS: 75330-75-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Lovastatin Request for quotation
CAS: 75330-75-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 75330-75-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Lovastatin Visit Supplier Webpage Request for quotationCAS: 75330-75-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Lovastatin Request for quotation
CAS: 75330-75-5
Tel: 86-10-10086 81625225
Email: yeqim@boyechemicals.com
Mobile: 86-15387090420
QQ: 1377812380
Wechat: 15387090420
CAS: 75330-75-5
Tel: 86-10-10086 81625225
Email: yeqim@boyechemicals.com
Mobile: 86-15387090420
QQ: 1377812380
Wechat: 15387090420
Product Name: LOVASTATIN Request for quotation
CAS: 75330-75-5
Tel: 02787737261
Email: 2295636945@qq.com
Mobile: 15387132319
QQ: 2295636945
Send QQ message
CAS: 75330-75-5
Tel: 02787737261
Email: 2295636945@qq.com
Mobile: 15387132319
QQ: 2295636945
Multiple SpecificationsSpot supply
Product Name: Simvastatin Impurity 5（Simvastatin EP Impurity E） Visit Supplier Webpage Request for quotationCAS: 75330-75-5
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Lovastatin Request for quotation
CAS: 75330-75-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 75330-75-5
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Lovastatin Visit Supplier Webpage Request for quotationCAS: 75330-75-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Lovastatin Request for quotation
CAS: 75330-75-5
Tel: 86-10-10086 81625225
Email: yeqim@boyechemicals.com
Mobile: 86-15387090420
QQ: 1377812380
Wechat: 15387090420
CAS: 75330-75-5
Tel: 86-10-10086 81625225
Email: yeqim@boyechemicals.com
Mobile: 86-15387090420
QQ: 1377812380
Wechat: 15387090420
Product Name: LOVASTATIN Request for quotation
CAS: 75330-75-5
Tel: 02787737261
Email: 2295636945@qq.com
Mobile: 15387132319
QQ: 2295636945Send QQ message
CAS: 75330-75-5
Tel: 02787737261
Email: 2295636945@qq.com
Mobile: 15387132319
QQ: 2295636945
View History